Skip to content

US · ENOV · MEDICAL - DEVICES

Enovis Corporation (ENOV) intrinsic value and stock valuation

$25.47as of 2026-11-21 · Mkt cap 1.53B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Enovis Corporation DCF and intrinsic value

InvestorsCraft values ENOV with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ENOV’s statements →

Enovis Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Wilmington, DE 19808 enovis.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.25B+14.9% 5y CAGRd
20112025
Net income
-$-1.18B
20112025
Free cash flow
$19.9M-36.1% 5y CAGRd
20112025
Total equity
$1.49B-16.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.25B$2.11B$1.71B$1.56B$1.43B
Operating income-$-18.87M-$-775.72M-$-65.71M-$-71.18M-$-62.8M
Net income-$-1.18B-$-825.49M-$-33.26M-$-13.29M$71.7M
EPSd-$-20.86M-$-14.93M-$-610.39K-$-245.79K$1.4M
Operating cash flow$217.3M$113.5M$135M-$-55.86M$356.1M
Capital expenditure-$-197.38M-$-180.71M-$-122.22M-$-105.45M-$-104.24M
Free cash flow$19.9M-$-67.21M$12.8M-$-161.31M$251.9M
Total assets$3.83B$4.72B$4.51B$4.27B$8.52B
Total debt$1.38B$1.4B$536.4M$334.8M$2.16B
Net debt$1.34B$1.36B$500.2M$310.5M$1.48B
Total equity$1.49B$2.56B$3.42B$3.45B$4.66B
Cash and short-term investments$36.4M$48.2M$36.2M$24.3M$680.3M
Income statement
20252024202320222021
Revenue$2.25B$2.11B$1.71B$1.56B$1.43B
Cost of revenue$902.8M$926.9M$716.4M$693.7M$648.5M
Gross profit$1.35B$1.18B$990.8M$869.4M$777.7M
Research and development expenses$120.3M$91.3M$75.3M$60.8M$49.1M
Selling, general and administrative expenses$1.07B$939.4M$830.3M$772.9M$665.8M
Other expenses$173.7M$925.8M$150.9M$106.8M$125.6M
Operating expenses$1.36B$1.96B$1.06B$940.6M$840.5M
Cost and expenses$2.27B$2.88B$1.77B$1.63B$1.49B
Interest income$0.00$0.00$0.00$200K$0.00
Interest expense$34.8M$57.1M$19.8M$25M$29.1M
Depreciation and amortization$294.4M$284.8M$217.1M$219.7M$262.9M
Ebitda-$-830.22M-$-481.03M$169.7M$241.7M$170.3M
Operating income-$-18.87M-$-775.72M-$-65.71M-$-71.18M-$-62.8M
Total other income/expenses, net-$-1.14B-$-47.2M-$-1.42M$69.1M-$-58.98M
Income before tax-$-1.16B-$-822.92M-$-67.13M-$-2.07M-$-121.78M
Income tax expense$22.3M$4.49M-$-13.29M$36.1M-$-19.53M
Net income-$-1.18B-$-825.49M-$-33.26M-$-13.29M$71.7M
Weighted average shares outstanding$56.8M$55.3M$54.5M$54.1M$51.1M
Weighted average diluted shares outstanding$56.8M$55.3M$54.5M$54.1M$51.1M
Balance sheet
20252024202320222021
Cash and short-term investments$36.4M$48.2M$36.2M$24.3M$680.3M
Net receivables$442.8M$407M$291.5M$267.4M$255M
Inventory$584.4M$547.1M$468.8M$426.6M$356.2M
Total current assets$1.21B$1.15B$896.5M$795M$2.3B
Property, plant and equipment, net$579.3M$473.4M$334.3M$303.6M$311.6M
Goodwill and intangible assets$1.96B$3.01B$3.19B$3.09B$3.09B
Long-term investments$21.4M$20.4M$0.00$16.5M$15.4M
Total non-current assets$2.63B$3.57B$3.61B$3.48B$6.21B
Total assets$3.83B$4.72B$4.51B$4.27B$8.52B
Accounts payable$187.5M$179.1M$132.5M$135.6M$155.2M
Short-term debt$59.7M$42.4M$21.6M$243.6M$29.6M
Deferred revenue$6.5M$6.23M$2.95M$3.56M$9.2M
Total current liabilities$598.5M$529M$369.6M$565.2M$1.02B
Long-term debt$1.32B$1.36B$514.9M$91.3M$2.14B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.74B$1.63B$719M$258.3M$2.83B
Capital lease obligations$58M$74.8M$48.7M$51.3M$56.6M
Total liabilities$2.34B$2.15B$1.09B$823.5M$3.85B
Common stock$60K$60K$60K$50K$50K
Retained earnings-$-1.47B-$-283.02M$542.5M$575.7M$589M
Accumulated other comprehensive income (loss)-$-91.36M-$-127.89M-$-24.88M-$-53.43M-$-516.01M
Total equity$1.49B$2.56B$3.42B$3.45B$4.66B
Total investments$21.4M$20.4M$0.00$16.5M$15.4M
Total debt$1.38B$1.4B$536.4M$334.8M$2.16B
Net debt$1.34B$1.36B$500.2M$310.5M$1.48B
Cash flow statement
20252024202320222021
Net income-$-1.18B-$-824.82M-$-33.26M-$-11.76M$76.3M
Depreciation and amortization$294.4M$284.8M$217.1M$219.7M$262.9M
Stock-based compensation$32.9M$29.7M$34.1M$39M$35.4M
Change in working capital$15.5M-$-13.93M-$-27.27M-$-220.49M-$-17.1M
Accounts receivable-$-10.75M-$-57.05M-$-16.32M-$-45.19M-$-110.98M
Inventory-$-11.98M$39.1M-$-24.74M-$-118.79M-$-129.97M
Accounts payable-$-1.14M$14M-$-6.64M-$-11.84M$178.5M
Net cash provided by operating activities$217.3M$113.5M$135M-$-55.86M$356.1M
Investments in property, plant and equipment-$-197.38M-$-180.71M-$-122.22M-$-105.45M-$-104.24M
Acquisitions, net$16.4M-$-769.91M-$-152.81M-$-73.68M-$-223.27M
Net cash used for investing activities-$-179.37M-$-955.47M-$-242.47M-$-176.39M-$-320.48M
Common stock issued$1.32M$1.87M$1.78M$5.81M$745.2M
Common stock repurchased$0.00-$-4.77M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-52.4M$846.8M$127.8M-$-465.13M$584.9M
Net change in cash-$-11.78M$3.33M$20.5M-$-695.08M$618.3M
Cash at end of period$36.4M$48.2M$44.8M$24.3M$719.4M
Operating cash flow$217.3M$113.5M$135M-$-55.86M$356.1M
Capital expenditure-$-197.38M-$-180.71M-$-122.22M-$-105.45M-$-104.24M
Free cash flow$19.9M-$-67.21M$12.8M-$-161.31M$251.9M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Enovis Corporation

        Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.

        CEO
        Damien McDonald
        Employees
        7.8K
        Beta
        1.45

        Explore

        Frequently asked questions

        What is the intrinsic value of Enovis Corporation (ENOV)?

        Enovis Corporation (ENOV) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ENOV undervalued?

        ENOV trades at a price of $25.47 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.